Amgen Lung-Cancer Drug That Targets Mutation Cleared in U.S. (1)

May 28, 2021, 5:04 PM

Amgen Inc.’s lung-cancer treatment sotorasib won approval from U.S. regulators, becoming the first therapy to target a tumor-stoking genetic mutation scientists have tried to block for decades.

The Food and Drug Administration clearance, while only for a small group of patients, is a milestone for oncology. The drug is the first to directly target a mutant gene called KRAS G12C that’s present in about 13% of non-small-cell lung cancers.

KRAS is a growth-promoting gene that’s mutated in numerous lung, colon and pancreatic tumors. The mutations cause a key protein to send constant signals for cells to grow and proliferate. ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.